Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–12.
Article
CAS
PubMed
Google Scholar
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic Anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97:839–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chefdeville A, Honnorat J, Hampe CS, Desestret V. Neuronal central nervous system syndromes probably mediated by autoantibodies. Eur J Neurosci. 2016;43:1535–52.
Article
PubMed
PubMed Central
Google Scholar
Seldin MF. The genetics of human autoimmune disease: a perspective on progress in the field and future directions. J Autoimmun. 2015;64:1–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gough SC, Simmonds MJ. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics. 2007;8:453–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Caillat-Zucman S. New insights into the understanding of MHC associations with immune-mediated disorders: MHC-associated immune diseases. HLA. 2017;89:3–13.
Article
CAS
PubMed
Google Scholar
Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev Immunol. 2018;18:325–39.
Article
CAS
PubMed
Google Scholar
Klein J, Sato A. The HLA System. N Engl J Med. 2000;343:702–9.
Article
CAS
PubMed
Google Scholar
Lokki M, Paakkanen R. The complexity and diversity of MHC challenge disease association studies. HLA. 2019;93:3–15.
CAS
PubMed
Google Scholar
Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet. 2013;14:301–23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G, Euronetwork PNS. Paraneoplastic neurologic syndrome in the PNS euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67:330–5.
Article
PubMed
Google Scholar
Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.
Article
CAS
PubMed
Google Scholar
McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol. 2011;122:381–400.
Article
CAS
PubMed
Google Scholar
Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest. 2009;119:2042–51.
CAS
PubMed
PubMed Central
Google Scholar
Honnorat J, Didelot A, Karantoni E, Ville D, Ducray F, Lambert L, et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology. 2013;80:2226–32.
Article
CAS
PubMed
Google Scholar
Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Uchuya M, Fleury A, Graus F, Costagliola D, Liblau R, Merle-Beral H, et al. Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. Neurology. 1998;50:565–6.
Article
CAS
PubMed
Google Scholar
Tanaka K, Nakano R, Inuzuka T, Tsuji S, Shinozawa K, Kojo T, et al. Lack of association between human leukocyte antigens and anti-Hu syndrome in patients with small-cell lung cancer. Neurology. 1999;52:431.
Article
CAS
PubMed
Google Scholar
Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics. 1999;50:201–12.
Article
CAS
PubMed
Google Scholar
Tanaka M, Maruyama Y, Sugie M, Motizuki H, Kamakura K, Tanaka K. Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J Neurol Sci. 2002;201:9–12.
Article
CAS
PubMed
Google Scholar
de Graaf MT, de Beukelaar JWK, Haasnoot GW, Levering WH, Rogemond V, Didelot A, et al. HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol. 2010;226:147–9.
Article
PubMed
CAS
Google Scholar
McKeon A, Tracey JA, Pittock SJ, Parisi JE, Klein CJ, Lennon VA. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol. 2011;68:1282–9.
Article
PubMed
Google Scholar
Kråkenes T, Herdlevær I, Raspotnig M, Haugen M, Schubert M, Vedeler CA. CDR2L Is the major Yo antibody target in paraneoplastic cerebellar degeneration. Ann Neurol. 2019;86:316–21.
Article
PubMed
CAS
Google Scholar
Small M, Treilleux I, Couillault C, Pissaloux D, Picard G, Paindavoine S, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol. 2018;135:569–79.
Article
CAS
PubMed
Google Scholar
Tanaka M, Tanaka K. HLA A24 in paraneoplastic cerebellar degeneration with anti-Yo antibody. Neurology. 1996;47:606–7.
Article
CAS
PubMed
Google Scholar
Tanaka M, Tanaka K, Tsuji S, Kawata A, Kojima S, Kurokawa T, et al. Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration. J Neurol Sci. 2001;188:61–5.
Article
CAS
PubMed
Google Scholar
Hillary RP, Ollila HM, Lin L, Desestret V, Rogemond V, Picard G, et al. Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. J Neuroimmunol. 2018;315:28–32.
Article
CAS
PubMed
Google Scholar
Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104:359–63.
Article
PubMed
Google Scholar
Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10:1098–107.
Article
PubMed
Google Scholar
Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol. 2005;165:166–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Willcox N, Demaine AG, Newsom-Davis J, Welsh KI, Robb SA, Spiro SG. Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma. Hum Immunol. 1985;14:29–36.
Article
CAS
PubMed
Google Scholar
Parsons KT, Kwok WW, Gaur LK, Nepom GT. Increased frequency of HLA class II alleles DRB1∗0301 and DQB1∗0201 in Lambert-Eaton myasthenic syndrome without associated cancer. Hum Immunol. 2000;61:828–33.
Article
CAS
PubMed
Google Scholar
Wirtz PW, Roep BO, Schreuder GMT, van Doorn PA, van Engelen GM, Kuks JB, et al. HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor. Hum Immunol. 2001;62:809–13.
Article
CAS
PubMed
Google Scholar
Wirtz PW, Willcox N, Roep BO, Lang B, Wintzen AR, Newsom-Davis J, et al. HLA-B8 in patients with the Lambert-Eaton myasthenic syndrome reduces likelihood of associated small cell lung carcinoma. Ann N Y Acad Sci. 2003;998:200–1.
Article
CAS
PubMed
Google Scholar
Wirtz PW, Willcox N, van der Slik AR, Lang B, Maddison P, Koeleman BP, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol. 2005;159:230–7.
Article
CAS
PubMed
Google Scholar
Cetin H, Vincent A. Pathogenic mechanisms and clinical correlations in autoimmune myasthenic syndromes. Semin Neurol. 2018;38:344–54.
Article
PubMed
Google Scholar
Sharp L, Vernino S. Paraneoplastic neuromuscular disorders. Muscle Nerve. 2012;46:841–50.
Article
PubMed
Google Scholar
Maniaol AH, Elsais A, Lorentzen ÅR, Owe JF, Viken MK, Sæther H, et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS ONE. 2012;7:e36603.
Article
CAS
PubMed
PubMed Central
Google Scholar
Popperud TH, Viken MK, Kerty E, Lie BA. Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset. PLoS ONE. 2017;12:e0186383.
Article
CAS
PubMed
PubMed Central
Google Scholar
Feng X, Li W, Song J, Liu X, Gu Y, Yan C, et al. HLA typing using next-generation sequencing for Chinese juvenile- and adult-onset myasthenia gravis patients. J Clin Neurosci. 2019;59:179–84.
Article
PubMed
Google Scholar
Machens A, Löliger C, Pichlmeier U, Emskötter T, Busch C, Izbicki JR. Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol. 1999;91:296–301.
Article
CAS
PubMed
Google Scholar
Giraud M, Beaurain G, Yamamoto AM, Eymard B, Tranchant C, Gajdos P, et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology. 2001;57:1555–60.
Article
CAS
PubMed
Google Scholar
Saruhan-Direskeneli G, Kiliç A, Parman Y, Serdaroglu P, Deymeer F. HLA-DQ polymorphism in Turkish patients with myasthenia gravis. Hum Immunol. 2006;67:352–8.
Article
CAS
PubMed
Google Scholar
Saruhan-Direskeneli G, Hughes T, Yilmaz V, Durmus H, Adler A, Alahgholi-Hajibehzad M, et al. Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. Clin Immunol. 2016;166–167:81–8.
Article
PubMed
CAS
Google Scholar
Santos E, Bettencourt A, da Silva AM, Boleixa D, Lopes D, Brás S, et al. HLA and age of onset in myasthenia gravis. Neuromuscul Disord. 2017;27:650–4.
Article
PubMed
Google Scholar
Varade J, Wang N, Lim CK, Zhang T, Zhang Y, Liu X, et al. Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis. J Autoimmun. 2018;88:43–9.
Article
CAS
PubMed
Google Scholar
Deitiker PR, Oshima M, Smith RG, Mosier D, Atassi MZ. Association with HLA DQ of early onset myasthenia gravis in Southeast Texas region of the United States: HLA DQ risk factors for myasthenia gravis in Southeast Texas. Int J Immunogenet. 2011;38:55–62.
Article
CAS
PubMed
Google Scholar
Xie Y, Qu Y, Sun L, Li H, Zhang H, Shi H, et al. Association between HLA-DRB1 and myasthenia gravis in a northern Han Chinese population. J Clin Neurosci. 2011;18:1524–7.
Article
CAS
PubMed
Google Scholar
Ehsan S, Amirzargar A, Yekaninejad MS, Mahmoudi M, Mehravar S, Moradi B, et al. Association of HLA class II (DRB1, DQA1, DQB1) alleles and haplotypes with myasthenia gravis and its subgroups in the Iranian population. J Neurol Sci. 2015;359:335–42.
Article
CAS
PubMed
Google Scholar
Testi M, Terracciano C, Guagnano A, Testa G, Marfia GA, Pompeo E, et al. Association of HLA-DQB1*05:02 and DRB1*16 Alleles with late-onset, nonthymomatous, AChR-Ab-positive myasthenia gravis. Autoimmune Dis. 2012;2012:1–3.
Article
CAS
Google Scholar
Massa R, Greco G, Testi M, Rastelli E, Terracciano C, Frezza E, et al. Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity. J Neurol. 2019;266:982–9.
Article
PubMed
Google Scholar
Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol. 2011;230:148–52.
Article
CAS
PubMed
Google Scholar
Shinomiya N, Nomura Y, Segawa M. A variant of childhood-onset myasthenia gravis: HLA typing and clinical characteristics in Japan. Clin Immunol. 2004;110:154–8.
Article
CAS
PubMed
Google Scholar
Niks EH, Kuks JBM, Roep BO, Haasnoot GW, Verduijn W, Ballieux BE, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology. 2006;66:1772–4.
Article
CAS
PubMed
Google Scholar
Bartoccioni E, Scuderi F, Augugliaro A, Chiatamone Ranieri S, Sauchelli D, Alboino P, et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology. 2009;72:195–7.
Article
CAS
PubMed
Google Scholar
Alahgholi-Hajibehzad M, Yilmaz V, Gülsen-Parman Y, Aysal F, Oflazer P, Deymeer F, et al. Association of HLA-DRB1∗14, -DRB1∗16 and -DQB1∗05 with MuSK-myasthenia gravis in patients from Turkey. Hum Immunol. 2013;74:1633–5.
Article
CAS
PubMed
Google Scholar
Nikolic AV, Andric ZP, Simonovic RB, Rakocevic Stojanovic VM, Basta IZ, Bojic SD, et al. High frequency of DQB1*05 and absolute absence of DRB1*13 in muscle-specific tyrosine kinase positive myasthenia gravis. Eur J Neurol. 2015;22:59–63.
Article
CAS
PubMed
Google Scholar
Kanai T, Uzawa A, Kawaguchi N, Sakamaki T, Yoshiyama Y, Himuro K, et al. HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients. J Neurol Sci. 2016;363:116–8.
Article
CAS
PubMed
Google Scholar
Hong Y, Li H-F, Romi F, Skeie GO, Gilhus NE. HLA and MuSK-positive myasthenia gravis: a systemic review and meta-analysis. Acta Neurol Scand. 2018;138:219–26.
Article
CAS
PubMed
Google Scholar
Yang H, Hao J, Peng X, Simard AR, Zhang M, Xie Y, et al. The association of HLA-DQA1*0401 and DQB1*0604 with thymomatous myasthenia gravis in northern Chinese patients. J Neurol Sci. 2012;312:57–61.
Article
CAS
PubMed
Google Scholar
Vandiedonck C, Raffoux C, Eymard B, Tranchant C, Dulmet E, Krumeich S, et al. Association of HLA-A in autoimmune myasthenia gravis with thymoma. J Neuroimmunol. 2009;210:120–3.
Article
CAS
PubMed
Google Scholar
Querol L, Nogales-Gadea G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014;82:879–86.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, Matsuse D, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol. 2015;2:960–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016;86:800–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Morena A, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149.
Article
PubMed
PubMed Central
Google Scholar
Diaz-Manera J, Martinez-Hernandez E, Querol L, Klooster R, Rojas-Garcia R, Suarez-Calvet X, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78:189–93.
Article
CAS
PubMed
Google Scholar
Martinez-Martinez L, MaC Lleixà, Boera-Carnicero G, Cortese A, Devaux J, Siles A, et al. Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. J Neuroinflammation. 2017;14(1):224.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575–86.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736–43.
Article
CAS
PubMed
PubMed Central
Google Scholar
Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4:e385.
Article
PubMed
PubMed Central
Google Scholar
Bonello M, Jacob A, Ellul MA, Barker E, Parker R, Jefferson S, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017;4:e383.
Article
PubMed
PubMed Central
Google Scholar
Moreno-Estébanez A, Garcia-Ormaechea M, Tijero B, Fernandez-Valle T, Gomez-Esteban JC, Berganzo K. Anti-IgLON5 disease responsive to immunotherapy: a case report with an abnormal MRI. Mov Disord Clin Pract. 2018;5:653–6.
Article
PubMed
PubMed Central
Google Scholar
Logmin K, Moldovan AS, Elben S, Schnitzler A, Groiss SJ. Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathy. J Neurol. 2019;266:1031–3.
Article
CAS
PubMed
Google Scholar
Gaig C, Ercilla G, Daura X, Ezquerra M, Fernandez-Santiago R, Palou E, et al. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm. 2019;6:e605.
Article
PubMed
PubMed Central
Google Scholar
Montagna M, Amir R, De Volder I, Lammens M, Huyskens J, Willekens B. IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes. Front Neurol. 2018;9:329.
Article
PubMed
PubMed Central
Google Scholar
Simabukuro MM, Sabater L, Adoni T, Gisbert R, Haddad MS, Moreira CH, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e136.
Article
PubMed
PubMed Central
Google Scholar
Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10:835–44.
Article
PubMed
Google Scholar
Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83:166–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69:892–900.
Article
PubMed
Google Scholar
van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology. 2016;87:1449–56.
Article
PubMed
CAS
Google Scholar
Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain. 2016;139:1079–93.
Article
PubMed
Google Scholar
Kim T-J, Lee S-T, Moon J, Sunwoo J-S, Byun J-I, Lim J-A, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes: HLA subtypes in Anti-LGI1 encephalitis. Ann Neurol. 2017;81:183–92.
Article
CAS
PubMed
Google Scholar
van Sonderen A, Roelen DL, Stoop JA, Verdijk RM, Haasnoot GW, Thijs RD, et al. Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4: anti-LGI1 encephalitis. Ann Neurol. 2017;81:193–8.
Article
PubMed
CAS
Google Scholar
Binks S, Varley J, Lee W, Makuch M, Elliot K, Gelfand JM, et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain. 2018;141:2263–71.
Article
PubMed
PubMed Central
Google Scholar
Vogrig A, Joubert B, André-Obadia N, Gigli GL, Rheims S, Honnorat J. Seizure specificities in patients with antibody-mediated autoimmune encephalitis. Epilepsia. 2019;60:1508–25.
Article
PubMed
Google Scholar
van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger KP, et al. The clinical spectrum of Caspr2 antibody–associated disease. Neurology. 2016;87:521–8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F, et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 2016;73:1115–24.
Article
PubMed
Google Scholar
Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72:241–55.
Article
PubMed
Google Scholar
Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project. Clin Infect Dis. 2012;54:899–904.
Article
CAS
PubMed
PubMed Central
Google Scholar
Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bost C, Chanson E, Picard G, Meyronet D, Mayeur ME, Ducray F, et al. Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. J Neurol. 2018;265:2190–200.
Article
CAS
PubMed
Google Scholar
Armangue T, Spatola M, Vlagea A, Mattozzi S, Carceles-Cordon M, Martinez-Heras E, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17:760–72.
Article
PubMed
PubMed Central
Google Scholar
Mueller SH, Färber A, Prüss H, Melzer N, Golombeck KS, Kümpfel T, et al. Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis: GWAS autoimmune encephalitis. Ann Neurol. 2018;83:863–9.
Article
CAS
PubMed
Google Scholar
Shu Y, Qiu W, Zheng J, Sun X, Yin J, Yang X, et al. HLA class II allele DRB1*16:02 is associated with anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry. 2019;90:652–8.
Article
PubMed
Google Scholar
Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553–63.
Article
PubMed
Google Scholar
Gresa-Arribas N, Ariño H, Martínez-Hernández E, Petit-Pedrol M, Sabater L, Saiz A, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS ONE. 2015;10:e0121364.
Article
PubMed
PubMed Central
CAS
Google Scholar
Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol. 2001;58:225–30.
Article
CAS
PubMed
Google Scholar
Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff- person syndrome. Neurology. 2000;55:1531–5.
Article
CAS
PubMed
Google Scholar
Pugliese A, Solimena M, Awdeh ZL, Alper CA, Bugawan T, Erlich HA, et al. Association of HLA-DQB1*0201 with stiff-man syndrome. J Clin Endocrinol Metab. 1993;77:1550–3.
CAS
PubMed
Google Scholar
Costa M, Saiz A, Casamitjana R, Fernandez-Castañer M, Sanmarti A, Graus F. T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity. Clin Exp Immunol. 2002;129:471–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Belbezier A, Joubert B, Montero-Martin G, Fernandez-Vina M, Fabien N, Rogemond V, et al. Multiplex family with GAD65-Abs neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2018;5:e416.
Article
PubMed
Google Scholar
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89.
Article
PubMed
PubMed Central
Google Scholar
Alonso VR, de Jesus Flores Rivera J, Garci YR, Granados J, Sanchez T, Mena-Hernandez L, et al. Neuromyelitis optica (NMO IgG+) and genetic susceptibility, potential ethnic influences. Centr Nerv Syst Agents Med Chem. 2018;18:4–7.
CAS
Google Scholar
Zéphir H, Fajardy I, Outteryck O, Blanc F, Roger N, Fleury M, et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler. 2009;15:571–9.
Article
PubMed
Google Scholar
Guimaraães Brum D, Barreira AA, dos Santos AC, Kaimen-Maciel DR, Matiello M, Costa RM, et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler. 2010;16:21–9.
Article
CAS
Google Scholar
Deschamps R, Paturel L, Jeannin S, Chausson N, Olindo S, Bera O, et al. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population. Mult Scler. 2011;17:24–31.
Article
CAS
PubMed
Google Scholar
Blanco Morgado Y, Ercilla González G, Llufriu Durán S, Casanova-Estruch B, Magraner MJ, Ramio-Torrenta L, et al. HLA-DRB1 en pacientes caucásicos con neuromielitis óptica. Rev Neurol. 2011;53:146.
Google Scholar
Pandit L, Malli C, D’Cunha A, Mustafa S. Human leukocyte antigen association with neuromyelitis optica in a south Indian population. Mult Scler. 2015;21:1217–8.
Article
PubMed
Google Scholar
Alvarenga MP, Fernandez O, Leyva L, Campanella L, Vasconcelos CF, Alvarenga M, et al. The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro. J Neuroimmunol. 2017;310:1–7.
Article
CAS
PubMed
Google Scholar
Asgari N, Nielsen C, Stenager E, Kyvik KO, Lillevang ST. HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica. Mult Scler. 2012;18:23–30.
Article
CAS
PubMed
Google Scholar
Brill L, Mandel M, Karussis D, Petrou P, Miller K, Ben-Hur T, et al. Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel. J Neuroimmunol. 2016;293:65–70.
Article
CAS
PubMed
Google Scholar
Estrada K, Whelan CW, Zhao F, Bronson P, Handsaker RE, Sun C, et al. A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun. 2018;9(1):1929.
Article
PubMed
PubMed Central
CAS
Google Scholar
Isobe N, Matsushita T, Yamasaki R, Ramagopalan SV, Kawano Y, Nishimura Y, et al. Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. Mult Scler. 2010;16:147–55.
Article
CAS
PubMed
Google Scholar
Matsushita T, Matsuoka T, Isobe N, Kawano Y, Minohara M, Shi N, et al. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens. 2009;73:171–6.
Article
CAS
PubMed
Google Scholar
Wang H, Dai Y, Qiu W, Zhong X, Wu A, Wang Y, et al. HLA-DPB1*0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese. J Neuroimmunol. 2011;233:181–4.
Article
CAS
PubMed
Google Scholar
Yoshimura S, Isobe N, Matsushita T, Yonekawa T, Masaki K, Sato S, et al. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry. 2013;84:29–34.
Article
PubMed
Google Scholar
Lee J-J, Tsai M-H, Lien C-Y, Huang Y-J, Chang W-N. Intra-family phenotype variations in familial neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019;30:57–62.
Article
PubMed
Google Scholar
Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79:1273–7.
Article
CAS
PubMed
Google Scholar
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90:e1858–69.
Article
CAS
PubMed
Google Scholar
Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol. 2015;22:1151–61.
Article
CAS
PubMed
Google Scholar